If this could be substantiated by the development or discovery of Slc9a6 mutants that selectively ablate its ion exchange capacity without affecting its subcellular sorting or interaction with cytoplasmic or luminal binding partners, this would further raise the potential of NHE6 as a novel drug target for neurodegenerative diseases. Here, SLC9A6 is linked to neurodegenerative disease.